logo
Scientists in a race to discover why the Universe exists

Scientists in a race to discover why the Universe exists

Yahoo13-05-2025

Inside a laboratory nestled above the mist of the forests of south Dakota, scientists are searching for the answer to one of science's biggest questions: why does the Universe exist?
They are in a race for the answer with a separate team of Japanese scientists – who are several years ahead.
The current theories of astronomy can't explain why the planets stars and galaxies came into existence. Both teams are building detectors that study a sub-atomic particle called a neutrino in the hope of finding answers.
US scientists are hoping the answer lies deep underground, in the aptly named Deep Underground Neutrino Experiment (Dune).
The scientists travel 1,500 metres below the surface into three vast underground caverns. Such is the scale that construction crews and their bulldozers seem like small plastic toys by comparison.
Dune's science director Dr Jaret Heise describes the giant caves as "cathedrals to science".
Dr Heise has been involved the construction of these caverns for nearly ten years. They seal Dune off from the noise and radiation from the world above. Now, Dune is now ready for the next stage.
"We are poised to build the detector that will change our understanding of the Universe with instruments that will be deployed by a collaboration of 1,500 scientists who are eager to answer the question of why we exist," he says.
When the Universe was created two kinds of particles were created: matter – from which stars, planets and everything around us are made – and, in equal amounts, antimatter, matter's exact opposite.
Theoretically the two should have cancelled each other out, leaving nothing but a big burst of energy. And yet, here we – as matter – are.
Scientists believe that the answer to understanding why matter won – and we exist – lies in studying a particle called the neutrino and its antimatter opposite, the anti-neutrino.
They will be firing beams of both kinds of particles from deep underground in Illinois to the detectors at South Dakota, 800 miles away.
This is because as they travel, neutrinos and anti-neutrinos change ever so slightly.
The scientists want to find out whether those changes are different for the neutrinos and anti-neutrinos. If they are, it could lead them to the answer of why matter and anti-matter don't cancel each other out.
Dune is an international collaboration, involving 1,400 scientists from thirty countries. Among them is Dr Kate Shaw from Sussex University, who told me that the discoveries in store will be "transformative" to our understanding of the Universe and humanity's view of itself.
"It is really exciting that we are here now with the technology, with the engineering, with the computer software skills to really be able to attack these big questions," she said.
Half a world away, Japanese scientists are using shining golden globes to search for the same answers. In all their splendour, look like a temple to science. The scientists are building Hyper K - which will be a bigger and better version of their existing neutrino detector, Super K.
The Japanese-led team will be ready to turn on their neutrino beam in less than two years, several years earlier than the American project. Just like Dune, Hyper K is an international collaboration. Dr Mark Scott of Imperial College, London believes his team is in pole position to make one of the biggest ever discoveries about the origin of the Universe.
"We switch on earlier and we have a larger detector, so we should have more sensitivity sooner than Dune," he says.
Having both experiments running together means that scientists will learn more than they would with just one, but, he says, "I would like to get there first!"
But Dr Linda Cremonesi, of Queen Mary University of London, who works for the US project, says that getting there first may not give the Japanese-led team the full picture of what is really going on.
"There is an element of a race, but Hyper K does not have yet all of the ingredients that they need to understand if neutrinos and anti-neutrinos behave differently".
The race may be on, but the first results are only expected in a few years' time. The question of just what happened at the beginning of time to bring us into existence remains a mystery – for now.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump admin live updates: White House drops NASA nominee with Musk ties

timea day ago

Trump admin live updates: White House drops NASA nominee with Musk ties

The senate was slated to vote on Jared Isaacman next week. 3:08 President Donald Trump on Friday claimed China violated its trade agreement with the U.S. and Treasury Secretary Scott Bessent said talks between the world's two largest economies stalled. This week, Trump's global tariff policy hit a major roadblock as two federal courts ruled he does not have the power to unilaterally impose some levies. The tariffs can stay in place, for now, as the court considers the administration's appeal. Meanwhile, Elon Musk is leaving his role as a "special government employee" but is expected to remain an unofficial adviser to Trump. Latest headlines: May 31, 2025, 4:24 PM EDT White House pulls NASA nominee Jared Isaacman, billionaire with Musk ties May 30, 2025, 8:11 PM EDT Trump touts US Steel-Nippon deal May 30, 2025, 6:13 PM EDT Trump says he's doubling tariffs on steel imports to 50% May 30, 2025, 2:42 PM EDT Trump on possible pardon for Diddy: 'I would certainly look at the facts' Here's how the news is developing. May 31, 2025, 4:24 PM EDT White House pulls NASA nominee Jared Isaacman, billionaire with Musk ties The White House withdrew Saturday the nomination of Jared Isaacman to become the next NASA administrator just days before his scheduled confirmation vote in the Senate. "It's essential that the next leader of NASA is in complete alignment with President Trump's America First agenda and a replacement will be announced directly by President Trump soon," Liz Huston, a spokesperson for the White House said in a statement. Isaacman, who is the CEO of the payment processing company Shift4, has had a long history with Musk and worked with SpaceX on commercial flights into space. Isaacman attempted to distance himself from Musk during his confirmation hearing as he was getting grilled by Democrats on the committee. Musk and Trump have emphasized their desire to prioritize Mars, whereas Isaacman clarified during questioning that a lunar landing would take precedence over a Mars mission. In a post on social media, Trump confirmed he had pulled the nomination. "After a thorough review of prior associations, I am hereby withdrawing the nomination of Jared Isaacman to head NASA," Trump said without elaborating. "I will soon announce a new Nominee who will be Mission aligned, and put America First in Space." May 30, 2025, 8:11 PM EDT Trump touts US Steel-Nippon deal President Donald Trump on Friday touted a "blockbuster agreement" between U.S. Steel and Japanese company Nippon Steel that he said would keep the iconic U.S. steelmaker in Pittsburgh -- though he previously opposed such a merger and offered few details on the intricacies of the deal. Trump discussed the deal during a rally at the Irvin Works plant in Allegheny County on Friday evening. President Donald Trump said he will double the tariff imposed on imports of steel from 25% to 50%. Trump made the announcement during a rally in Pennsylvania on Friday to discuss the "partnership" between U.S. Steel and Japan-based Nippon Steel. Trump said the increase in steel tariffs "will even further secure the steel industry in the United States." Trump imposed the 25% tariffs on steel and aluminum in March, about a month before he announced sweeping across-the-board tariffs on what he called " Liberation Day." In a follow-up post on social media, Trump said the increased rate would go into effect June 4. May 30, 2025, 2:51 PM EDT Musk says his child punched him in the face Elon Musk, wearing all black, had a visible bruise over his right eye while speaking at the Oval Office. Asked what happened, Musk said his 5-year-old son punched him in the face. "I said, 'Go ahead, punch me in the face.' And, he did," Musk said.

Cellares and Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan
Cellares and Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan

Yahoo

time3 days ago

  • Yahoo

Cellares and Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan

Integrated, automated facility will unlock next-generation, commercial-scale cell therapy manufacturing in Japan IDMO Smart Factory manufacturing capabilities will accelerate patient access for CAR-T and other cell therapies in the region SOUTH SAN FRANCISCO, Calif. & TOKYO, May 29, 2025--(BUSINESS WIRE)--Cellares, a pioneer in automated cell therapy manufacturing, in collaboration with Mitsui Fudosan, announces the establishment of Japan's first next-gen commercial production site for CAR-T cell therapies. The facility is under construction in Kashiwa City, a vibrant urban center located approximately 30 kilometers northeast of central Tokyo in Chiba Prefecture. As part of the extensive Tokyo metropolitan region, Kashiwa serves as a booming biotech hub. This groundbreaking Integrated Development and Manufacturing Organization (IDMO) Smart Factory is expected to provide employment to 350 people while enabling scalable and cost-effective cell therapy manufacturing, addressing an urgent need for patients in Japan and neighboring regions. The facility, set to open in partnership with Mitsui Fudosan, will utilize Cellares' state-of-the-art technology platforms, the Cell Shuttle™ and Cell Q™, to automate cell therapy manufacturing and quality control. The technology reduces batch prices by up to 50% and eliminates the manufacturing bottlenecks faced by conventional CDMOs that use manual processes. Additionally, the entire Smart Factory will be integrated and optimized to eliminate any downstream bottlenecks as well. "Cellares' new facility in Kashiwa City will enable our pharma clients to supply Japan from Japan. Manufacturing cell therapies locally simplifies cold chain logistics, accelerates vein-to-vein time and reduces cost," said Fabian Gerlinghaus, CEO and Co-Founder of Cellares. "Our Japanese IDMO Smart Factory is part of a broader strategy to be a global manufacturing partner for our clients and meet the total patient demand for cell therapies around the world." The new site's impact extends beyond patient care. By accelerating the availability of CAR-T treatments, this initiative has the potential to help advance the development and approval of CAR-T therapeutics in Japan. Once the IDMO Smart Factory is online, technical transfers between Cellares facilities in other regions are expected to be a seamless, rapid, software-enabled process. Thanks to fully automated processes on standardized technologies, tech transfer can now happen at digital speed. Dr. Toshihiko Doi, the Chairperson of the Kashiwa-no-ha Life Science Committee, shared, "For cancer patients in Japan, the establishment of this facility provides access to cutting-edge therapies that can make a critical difference in their fight against diseases. It marks a significant step toward eliminating the drug delivery lag time that has been a challenge for rare disease and oncology treatments." Mitsui Fudosan's robust network in Japan's life sciences industry has been instrumental in enabling this collaboration, ensuring the smooth dissemination of information to the pharmaceutical industry, government agencies, and the broader healthcare community. This announcement represents Cellares' commitment to expanding its footprint in Japan, paving the way for further collaborations and innovations. For more information, visit About Cellares Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company's Cell Shuttle™ integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers end-to-end automation. While the Cell Shuttle automates cell therapy manufacturing, the Cell Q™ automates quality control at high throughput, both for in-process and release QC. Cell Shuttles™ and Cell Qs™ will be deployed in Cellares' Smart Factories around the world, enabling each Smart Factory to produce 10 times as many cell therapy batches as a conventional CDMO with the same facility size and headcount. Partnering with Cellares enables academic medical centers, biotechnology companies, and pharmaceutical companies to accelerate cell therapy development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand. The company is headquartered in South San Francisco, California with its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. Cellares is building a global network of IDMO Smart Factories, with additional facilities under construction in Europe and Japan. The company is backed by world-class investors and has raised over $355 million in financing. For more information about Cellares, please visit About Mitsui Fudosan Co. Mitsui Fudosan is working to create new industries during this time of change in society and the economy. As a "Platformer," the company provides "Places" and "Communities" that bring together the ideas of companies, society, and individuals. In April 2024, it launched a Group's New Long-Term Vision, setting a strategy to explore areas beyond real estate. To support this, Innovation Promoting Division was established to drive innovation and help create new industries. At Kashiwa-no-ha Smart City, Mitsui Fudosan works with the public, private, and academic sectors to create a community where people can live healthy lives and where new life science industries can grow. View source version on Contacts Cellares ContactsInvestors:ir@ Media:pr@ Sign in to access your portfolio

Cellares and Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan
Cellares and Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan

Business Wire

time3 days ago

  • Business Wire

Cellares and Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan

SOUTH SAN FRANCISCO, Calif. & TOKYO--(BUSINESS WIRE)-- Cellares, a pioneer in automated cell therapy manufacturing, in collaboration with Mitsui Fudosan, announces the establishment of Japan's first next-gen commercial production site for CAR-T cell therapies. The facility is under construction in Kashiwa City, a vibrant urban center located approximately 30 kilometers northeast of central Tokyo in Chiba Prefecture. As part of the extensive Tokyo metropolitan region, Kashiwa serves as a booming biotech hub. This groundbreaking Integrated Development and Manufacturing Organization (IDMO) Smart Factory is expected to provide employment to 350 people while enabling scalable and cost-effective cell therapy manufacturing, addressing an urgent need for patients in Japan and neighboring regions. The facility, set to open in partnership with Mitsui Fudosan, will utilize Cellares' state-of-the-art technology platforms, the Cell Shuttle™ and Cell Q™, to automate cell therapy manufacturing and quality control. The technology reduces batch prices by up to 50% and eliminates the manufacturing bottlenecks faced by conventional CDMOs that use manual processes. Additionally, the entire Smart Factory will be integrated and optimized to eliminate any downstream bottlenecks as well. 'Cellares' new facility in Kashiwa City will enable our pharma clients to supply Japan from Japan. Manufacturing cell therapies locally simplifies cold chain logistics, accelerates vein-to-vein time and reduces cost,' said Fabian Gerlinghaus, CEO and Co-Founder of Cellares. 'Our Japanese IDMO Smart Factory is part of a broader strategy to be a global manufacturing partner for our clients and meet the total patient demand for cell therapies around the world.' The new site's impact extends beyond patient care. By accelerating the availability of CAR-T treatments, this initiative has the potential to help advance the development and approval of CAR-T therapeutics in Japan. Once the IDMO Smart Factory is online, technical transfers between Cellares facilities in other regions are expected to be a seamless, rapid, software-enabled process. Thanks to fully automated processes on standardized technologies, tech transfer can now happen at digital speed. Dr. Toshihiko Doi, the Chairperson of the Kashiwa-no-ha Life Science Committee, shared, 'For cancer patients in Japan, the establishment of this facility provides access to cutting-edge therapies that can make a critical difference in their fight against diseases. It marks a significant step toward eliminating the drug delivery lag time that has been a challenge for rare disease and oncology treatments.' Mitsui Fudosan's robust network in Japan's life sciences industry has been instrumental in enabling this collaboration, ensuring the smooth dissemination of information to the pharmaceutical industry, government agencies, and the broader healthcare community. This announcement represents Cellares' commitment to expanding its footprint in Japan, paving the way for further collaborations and innovations. For more information, visit About Cellares Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company's Cell Shuttle™ integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers end-to-end automation. While the Cell Shuttle automates cell therapy manufacturing, the Cell Q™ automates quality control at high throughput, both for in-process and release QC. Cell Shuttles™ and Cell Qs™ will be deployed in Cellares' Smart Factories around the world, enabling each Smart Factory to produce 10 times as many cell therapy batches as a conventional CDMO with the same facility size and headcount. Partnering with Cellares enables academic medical centers, biotechnology companies, and pharmaceutical companies to accelerate cell therapy development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand. The company is headquartered in South San Francisco, California with its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. Cellares is building a global network of IDMO Smart Factories, with additional facilities under construction in Europe and Japan. The company is backed by world-class investors and has raised over $355 million in financing. For more information about Cellares, please visit About Mitsui Fudosan Co. Mitsui Fudosan is working to create new industries during this time of change in society and the economy. As a "Platformer," the company provides "Places" and "Communities" that bring together the ideas of companies, society, and individuals. In April 2024, it launched a Group's New Long-Term Vision, setting a strategy to explore areas beyond real estate. To support this, Innovation Promoting Division was established to drive innovation and help create new industries. At Kashiwa-no-ha Smart City, Mitsui Fudosan works with the public, private, and academic sectors to create a community where people can live healthy lives and where new life science industries can grow.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store